BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer

BACKGROUND: Pancreatic cancer has become the third leading cause of cancer death with minimal improvements in outcome for over 40 years. Recent trials of therapies that target-defective DNA maintenance using poly (ADP-ribose) polymerase (PARP) inhibitors are showing promising results, yet invariably...

Descripción completa

Detalles Bibliográficos
Autores principales: Pishvaian, Michael J, Biankin, Andrew V, Bailey, Peter, Chang, David K, Laheru, Daniel, Wolfgang, Christopher L, Brody, Jonathan R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396101/
https://www.ncbi.nlm.nih.gov/pubmed/28291774
http://dx.doi.org/10.1038/bjc.2017.40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396101/
https://www.ncbi.nlm.nih.gov/pubmed/28291774
http://dx.doi.org/10.1038/bjc.2017.40

Ejemplares similares